Article ; Online: Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension.
Translational vision science & technology
2022 Volume 11, Issue 1, Page(s) 7
Abstract: Purpose: To evaluate the ocular hypotensive efficacy and safety of razuprotafib, a novel Tie2 activator, when used as an adjunct to latanoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).: Methods: Subjects with OAG or ... ...
Abstract | Purpose: To evaluate the ocular hypotensive efficacy and safety of razuprotafib, a novel Tie2 activator, when used as an adjunct to latanoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: Subjects with OAG or OHT and an unmedicated IOP from ≥22 mm Hg to <36 mm Hg were randomized to one of three treatment arms: razuprotafib every day (QD) + latanoprost; razuprotafib twice daily (BID) + latanoprost; or latanoprost monotherapy. The primary endpoint was change in mean diurnal IOP from baseline at day 28. Results: A total of 194 subjects were randomized, and 193 (99.5%) completed the study. Razuprotafib BID + latanoprost resulted in a significantly larger reduction in diurnal IOP than latanoprost alone (7.95 ± 0.26 mmHg vs. 7.04 ± 0.26 mm Hg, P < 0.05). A smaller improvement was observed after 14 days of treatment (7.62 ± 0.26 mm Hg vs. 7.03 ± 0.26 mm Hg, P = 0.11). Razuprotafib QD dosing did not demonstrate additional IOP lowering compared to latanoprost alone. Conjunctival hyperemia on Day 28 increased by 1.1 units on the four-point Efron scale two hours post dose from a baseline value of 0.6 units, and decreased thereafter. Conclusions: Topical ocular razuprotafib as an adjunct to latanoprost therapy was well tolerated and significantly reduced IOP in patients with OAG/OHT. Translational relevance: These data support the IOP lowering efficacy of targeting Tie2 activation in Schlemm's canal in the relevant patient population. |
---|---|
MeSH term(s) | Antihypertensive Agents/therapeutic use ; Glaucoma, Open-Angle/drug therapy ; Humans ; Intraocular Pressure ; Latanoprost ; Ocular Hypertension/drug therapy ; Prostaglandins F, Synthetic/therapeutic use |
Chemical Substances | Antihypertensive Agents ; Prostaglandins F, Synthetic ; Latanoprost (6Z5B6HVF6O) |
Language | English |
Publishing date | 2022-01-27 |
Publishing country | United States |
Document type | Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2674602-5 |
ISSN | 2164-2591 ; 2164-2591 |
ISSN (online) | 2164-2591 |
ISSN | 2164-2591 |
DOI | 10.1167/tvst.11.1.7 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.